State-by-state tracker

Compounded medication availability by state (2026)

Whether a compounded medication can reach your door depends on your state: on the pharmacies registered to ship there, on what your state’s pharmacy regulators have said, and on what OrderlyMeds actually carries. This hub tracks all of that for ten product lines, state by state, with one rule: a line we don’t ship shows up as a No, never as a missing row.

Facts last reviewed: November 16, 2026

Pick your state

The linked states below are built today: the original five (Texas, California, Florida, Ohio, North Carolina) plus the expansion states as each one’s research lands, chosen to cover both straightforward and heavily regulated markets. The rest of the country is being researched and added a few states at a time; a state becomes a link here the day its page is real.

The federal picture, stated once

Every state page links back to this section instead of restating it. Four cited facts define the layer that sits above all fifty states; each carries the date it was verified.

FDA resolved the tirzepatide shortage on December 19, 2024 and the semaglutide shortage on February 21, 2025; the compounding grace periods tied to those shortages expired in spring 2025. Source: FDA Drug Shortages.

On August 27, 2026, the U.S. Court of Appeals for the Fifth Circuit (OFA v. FDA, Nos. 25-10600/25-10758) affirmed FDA’s position that compounding essentially-copies of commercially available FDA-approved drugs falls outside sections 503A/503B; what remains lawful is patient-specific 503A compounding where the prescriber documents a clinically significant difference for that individual patient. Source: U.S. Court of Appeals for the Fifth Circuit.

Under the enforcement-discretion policy HHS announced October 27–29, 2026, six peptides — BPC-157, TB-500, KPV, Epitalon, Semax, and MOTS-c — may be lawfully compounded and sold by state-licensed 503A pharmacies while FDA’s final rulemaking on their bulks-list status is pending. This is a real, current pathway, and it is distinct from FDA’s unchanged Category-2 safety designations for these substances — the two facts coexist. Source: U.S. Department of Health and Human Services.

FDA has proposed removing semaglutide, tirzepatide, and liraglutide from the 503B bulks list (Federal Register, May 1, 2026). The comment period closed June 29, 2026, and the rule was not finalized as of November 16, 2026 — a live watch item for every page in this family. Source: Federal Register.

The ten product lines we track

GLP-1 (compounded semaglutide)

Our core line, with flat national pricing at every dose. Treatment page.

GLP-1/GIP (compounded tirzepatide)

The dual-agonist line, priced flat like everything else. Treatment page.

NAD+

Longevity family, available through the standard online flow. Treatment page.

Sermorelin

Longevity family. One state (Ohio) is paused pending review, and its page says why. Treatment page.

Glutathione

Not currently offered through OrderlyMeds in any state, listed because an honest matrix includes what is missing. Longevity treatments.

BPC-157

Offered through OrderlyMeds as a compounded injectable, in every state we serve. The two cited federal facts below are the canonical wording every state page carries, and they ship on an available line exactly as they ship on an unavailable one.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed BPC-157 in Category 2, and BPC-157 has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense BPC-157 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

TB-500

Offered through OrderlyMeds as a compounded injectable, in every state we serve. The two cited federal facts below are the canonical wording every state page carries, and they ship on an available line exactly as they ship on an unavailable one.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed TB-500 (thymosin beta-4 fragment) in Category 2, and TB-500 (thymosin beta-4 fragment) has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense TB-500 pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

KPV

Not currently offered through OrderlyMeds in any state, because our peptide lines are compounded as injectables and KPV is not. The two cited federal facts below are the canonical wording every state page carries.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed KPV in Category 2, and KPV has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense KPV pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

Epitalon

Offered through OrderlyMeds as a compounded injectable, in every state we serve. The two cited federal facts below are the canonical wording every state page carries, and they ship on an available line exactly as they ship on an unavailable one.

FDA’s evaluation of bulk drug substances for compounding under section 503A placed Epitalon in Category 2, and Epitalon has no FDA-approved indication. Under the enforcement-discretion policy HHS announced October 27–29, 2026, state-licensed 503A pharmacies may lawfully compound and dispense Epitalon pursuant to a valid patient-specific prescription while FDA’s final rulemaking on its bulks-list status is pending. Sources: FDA — 503A bulk drug substances (Category 2) · HHS — peptide compounding enforcement-discretion policy (Oct 2026).

MOTS-c

Offered through OrderlyMeds as a compounded injectable, in every state we serve. The HHS policy below limits this line to subcutaneous or intramuscular administration, which is why it is one we can carry. Its cited federal record is the canonical wording every state page carries for it, and it is deliberately not the wording the four lines above carry: MOTS-c’s FDA record differs from theirs, so it is stated and sourced on its own.

FDA has evaluated MOTS-c as a bulk drug substance nominated for the section 503A bulks list and proposed that neither MOTS-c (free base) nor MOTS-c acetate be included on it, and MOTS-c has no FDA-approved indication. MOTS-c was formerly listed in Category 2 of FDA’s interim compounding policy, and it is no longer on that active list as of FDA’s April 22, 2026 update, because the nomination was withdrawn by the nominator. FDA’s record for the substance notes a potential immunogenicity concern by certain routes and no clinical data in humans, and FDA presented MOTS-c to its Pharmacy Compounding Advisory Committee in July 2026. Under the enforcement-discretion policy HHS published October 30, 2026 at 91 FR 68526, HHS does not intend to act against a state-licensed pharmacy, Federal facility, or licensed physician compounding MOTS-c under section 503A, limited to subcutaneous or intramuscular administration, under a valid patient-specific prescription, and subject to the policy’s other conditions, while rulemaking on the bulks list is pending. That policy does not add MOTS-c to the bulks list and does not make it an FDA-approved drug. Sources: FDA — bulk drug substances that may present significant safety risks (Category 2 and withdrawn nominations) · FDA — PCAC briefing document, July 23–24, 2026 (MOTS-c proposals, points 7–8) · HHS — 91 FR 68526, enforcement-discretion policy for 503A peptide compounding.

Ready when you are

See if you’re eligible

Compounded semaglutide from $74/month for your first 2 months — provider visit, medication, syringes, and shipping all included, at the same price for every dose. No membership fees.

Check eligibility

Secure. Private. No commitment

The OrderlyMeds eligibility check on a phone

*Compounded medications are not FDA-approved and are not reviewed by the FDA for safety, effectiveness, or quality. Compounded GLP-1 medications are prescribed only when a licensed healthcare provider determines, based on an individual patient’s medical needs, that an FDA-approved drug is not appropriate or that a clinically significant difference exists, such as dosage form, strength, or excipient composition. All medications are prescribed based on an individual patient evaluation by a licensed healthcare provider. Compounded GLP-1 medications are not generic versions of FDA-approved drugs and are not intended to be substitutes for FDA-approved products. They differ in formulation and are prescribed only pursuant to an individualized medical determination by a licensed healthcare provider. Compounded medications are prepared by state-licensed pharmacies or FDA-registered outsourcing facilities, as applicable. FDA registration of the facility does not constitute FDA approval or endorsement of any compounded medication. Wegovy®, Zepbound®, and Mounjaro® are registered trademarks of their respective owners. We do not claim affiliation with or endorsement by these manufacturers.